Cargando…

Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease

Macrophage activation syndrome is the most frequent life-threatening complication of adult-onset Still’s disease. This is a nearly fatal case of a young patient, which has been refractory to corticosteroids, anakinra, tocilizumab, cyclosporine A, and etoposide, but eventually responded miraculously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levy, Ofer, Apel, Arie, Alhdor, Hossam, Mizrachi, Avraham, Agmon-Levin, Nancy, Koren-Michowitz, Maya, Amit-Vazina, Mirit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mesut Onat 2022
Materias:	Case-based Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089131/ https://www.ncbi.nlm.nih.gov/pubmed/35943464 http://dx.doi.org/10.5152/eurjrheum.2022.21064

Ejemplares similares

Elderly-onset adult Still’s disease
por: Mzabi, Anis, et al.
Publicado: (2021)

Timing of BNT162b2 vaccine prior to COVID‐19 infection, influence disease severity in patients with hematologic malignancies: Results from a cohort study
por: Gutwein, Odit, et al.
Publicado: (2023)

Refractory Adult Onset Still’s Disease
por: Sulaiman, Wahinuddin, et al.
Publicado: (2017)

Adult-onset Still’s disease complicated by macrophage activation syndrome during pregnancy: a case-based review
por: Wise, Leanna, et al.
Publicado: (2023)

Flare of adult-onset Still’s disease following mRNA COVID-19 vaccination: a case report and review of literature
por: Kim, Ji-Won, et al.
Publicado: (2022)

New-onset Adult-onset Still’s disease-like syndrome after ChAdOx1 nCoV-19 vaccination—a case series with review of literature
por: Padiyar, Shivraj, et al.
Publicado: (2022)

Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023)

Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL
por: Jaramillo, Sonia, et al.
Publicado: (2020)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
por: Pope, Eleanor, et al.
Publicado: (2022)

Successful treatment with tacrolimus of refractory adult-onset Still's disease
por: Ohe, Masashi, et al.
Publicado: (2014)

Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still’s Disease
por: Sun, Ziyi, et al.
Publicado: (2023)

Thrombocytopenia and thrombocytosis are associated with different outcome in atrial fibrillation patients on anticoagulant therapy
por: Michowitz, Yoav, et al.
Publicado: (2019)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still's Disease
por: Tsuji, Yoshika, et al.
Publicado: (2015)

Myocarditis as the Initial Presentation of a Refractory Adult-Onset Still’s Disease
por: Pina Gonçalves, Nuno, et al.
Publicado: (2022)

A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
por: Li, Ting, et al.
Publicado: (2017)

Experience with abatacept in refractory lupus nephritis
por: Calatayud, Emma, et al.
Publicado: (2023)

Two flares of Still’s disease after two doses of the ChAdOx1 vaccine
por: Roongta, Rashmi, et al.
Publicado: (2022)

Tofacitinib in Refractory Scleritis: A Case Series
por: Dey, Suvankar, et al.
Publicado: (2023)

A flare of Still’s disease following COVID-19 vaccination in a 34-year-old patient
por: Jeon, Young Hun, et al.
Publicado: (2021)

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
por: Maffini, Enrico, et al.
Publicado: (2016)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera
por: Swei, Eric C., et al.
Publicado: (2022)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
por: Al Sharie, Ahmed H., et al.
Publicado: (2023)

Letter in response to the case report “Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis”
por: Teklu, Meron, et al.
Publicado: (2023)

Publisher Correction: A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still’s Disease
por: Li, Ting, et al.
Publicado: (2018)

Oculomotor nerve palsy, an unusual onset of polyarteritis nodosa
por: Martins, Ana, et al.
Publicado: (2023)

Ruxolitinib: Thrombocytopenia following compassionate use of ruxolitinib: 2 case reports
Publicado: (2022)

Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study
por: Escamilla Gómez, Virginia, et al.
Publicado: (2019)

Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis
por: Fan, Shuang, et al.
Publicado: (2022)

Refractory Genital HPV Infection and Adult-Onset Still Disease: A Case Report and Literature Review
por: Yu, Xin, et al.
Publicado: (2016)

Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review
por: Ortiz-Sanjuán, Francisco, et al.
Publicado: (2015)

Adding colchicine to immunosuppressive treatments; a potential option for biologics-refractory adult-onset Still’s disease
por: Asano, Tomoyuki, et al.
Publicado: (2018)

Refractory adult-onset Still disease treated by tocilizumab combined with methotrexate: A STROBE-compliant article
por: Wang, Chun-yan, et al.
Publicado: (2019)

Refractory Urticaria with Raised Antistreptolysin O (ASO) Titer: An Intriguing Case of Adult-Onset Still’s Disease
por: Aldehaim, Abdulkarim Y., et al.
Publicado: (2020)

Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China
por: Hu, Qiongyi, et al.
Publicado: (2020)

Refractory adult-onset Still’s disease complicated with monoclonal gammopathy of undetermined significance: A case report
por: Saito, Kenji, et al.
Publicado: (2022)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s7lnrioobv60ka0bj551sreq9t